First tranche delivered, larger tranches en route: the same engine that just produced has visibly more already scheduled
The model's full reasoning — Q1 2022 call → NOWe need to determine if management describes one identifiable engine of new business with both: (1) a first tranche actually landed in the reported period, and (2) larger tranches already in motion behind it, with the remainder larger than what's been recognized. Let's scan the transcript for such an engine. Candidates: Moderna vaccine in Japan, Novavax vaccine, dengue vaccine, TAK-994, etc. Moderna vaccine: In Q1, they booked some revenue for Moderna vaccine in Japan. Costa said: "we did book some revenue for the Moderna vaccine in Japan in quarter 1." And later: "we expect to deliver mid-single digit spurred by the acceleration of our 14 global brands and also based – also driven by continued rollout of the Moderna vaccine here in Japan." Also Christophe mentioned expanded partnership to bring 100 million doses. But is the first tranche landed? Yes, they booked revenue. Is larger tranche already in motion? They have a partnership with Moderna to bring 100 million doses, and they are rolling out. But is the remainder larger than what's been recognized? They booked some revenue in Q1, and they expect continued rollout. However, the transcript also mentions delays in supply from Moderna due to manufacturing issues. Masato Iwasaki said: "Moderna's outside of U.S. partner in manufacturing, during its inspection process, some issues were found. Therefore, vaccine supply outside of U.S. has been delayed... we are ready, and we will focus on achieving those as quick as possible." So there is a delay. But the question is whether the continuation is already secured and in motion. The partnership is in place, but the supply is delayed. Management is not saying that the larger tranches are already committed and in motion; they are dealing with delays. Also, the first tranche is small relative to the total? They booked some revenue, but the total 100 million doses is the plan. However, the delay suggests that the larger tranches are not yet concretely underway; they are hoping to get supply. So this might not qualify. Another candidate: ENTYVIO new indication for pouchitis. They submitted to EMA, but that's a submission, not yet approved. Not landed. TAK-994 and TAK-999 got breakthrough designations, but that's pipeline, not business landed. What about the sale of diabetes portfolio? That's a one-time gain, not an engine.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| ATAT | Atour Lifestyle Holdings Limited | Q1 2024 | 2024-05-23 | B+ |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| E | Eni S.p.A. | Q1 2024 | 2024-04-24 | B+ |
| FRPH | FRP Holdings, Inc. | Q4 2023 | 2024-03-07 | C+ |
| ZLAB | Zai Lab Limited | Q4 2023 | 2024-02-28 | C |
| VMI | Valmont Industries, Inc. | Q4 2023 | 2024-02-22 | C |
| TBLA | Taboola.com Ltd. | Q3 2023 | 2023-11-08 | B+ |
| JLL | Jones Lang LaSalle Incorporated | Q3 2023 | 2023-11-02 | F |
| TEL | TE Connectivity Ltd. | Q4 2023 | 2023-11-01 | B |
| CLNE | Clean Energy Fuels Corp. | Q2 2023 | 2023-08-09 | C+ |
| LUCD | Lucid Diagnostics Inc. | Q1 2023 | 2023-05-16 | C+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| ARE | Alexandria Real Estate Equities, Inc. | Q4 2022 | 2023-01-31 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| CDMO | Avid Bioservices, Inc. | Q3 2022 | 2022-03-08 | B+ |
| DG | Dollar General Corporation | Q2 2021 | 2021-08-26 | A |
| DOV | Dover Corporation | Q2 2021 | 2021-07-20 | B+ |
| MAS | Masco Corporation | Q3 2018 | 2018-10-30 | C |
| FEIM | Frequency Electronics, Inc. | Q1 2019 | 2018-09-13 | B+ |
| SRDX | Surmodics, Inc. | Q3 2018 | 2018-08-06 | A |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| MGA | Magna International Inc. | Q1 2018 | 2018-05-10 | B+ |
| SATS | EchoStar Corporation | Q1 2018 | 2018-05-10 | C+ |
| RACE | Ferrari N.V. | Q3 2017 | 2017-11-02 | C+ |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| HR | Healthcare Realty Trust Incorporated | Q1 2017 | 2017-05-08 | A |
| BDN | Brandywine Realty Trust | Q1 2017 | 2017-04-21 | C+ |
| WTS | Watts Water Technologies, Inc. | Q4 2016 | 2017-02-10 | B |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| MTRX | Matrix Service Company | Q3 2016 | 2016-05-05 | D |
| CLF | Cleveland-Cliffs Inc. | Q1 2016 | 2016-04-29 | F |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
CDMO · Q3 2022 → YESThe question is about whether management describes ONE identifiable engine of new business that meets two criteria: NO The transcript describes the first phase of the Myford expansion as now operational and scheduling client projects, with management noting they are already utilizing the new space and that an extra $5 million is arguably in backlog attributable to it.
LINC · Q1 2024 → YESThe question is about whether management describes ONE identifiable engine of new business that meets two criteria: YES The transcript identifies the new-campus expansion strategy as the engine. East Point opened in Q1 with 29 starts and $90k revenue (first tranche, concrete and delivered).
LTRX · Q3 2024 → YESThe question is about whether management describes one identifiable engine of new business that meets two criteria: a first tranche has actually landed in the just-reported period, and larger tranches...